HDL, Atherosclerosis, and Emerging Therapies
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
This review aims to provide an overview on the properties of high-density lipoproteins (HDLs) and their cardioprotective effects. Emergent HDL therapies will be presented in the context of the current understanding of HDL function, metabolism, and protective antiatherosclerotic properties. The epidemiological association between levels of HDL-C or its major apolipoprotein (apoA-I) is strong, graded, and coherent across populations. HDL particles mediate cellular cholesterol efflux, have antioxidant properties, and modulate vascular inflammation and vasomotor function and thrombosis. A link of causality has been cast into doubt with Mendelian randomization data suggesting that genes causing HDL-C deficiency are not associated with increased cardiovascular risk, nor are genes associated with increased HDL-C, with a protective effect. Despite encouraging data from small studies, drugs that increase HDL-C levels have not shown an effect on major cardiovascular end-points in large-scale clinical trials. It is likely that the cholesterol mass within HDL particles is a poor biomarker of therapeutic efficacy. In the present review, we will focus on novel therapeutic avenues and potential biomarkers of HDL function. A better understanding of HDL antiatherogenic functions including reverse cholesterol transport, vascular protective and antioxidation effects will allow novel insight on novel, emergent therapies for cardiovascular prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · cited 2×
“Indeed in the Multi-Ethnic Study of Atherosclerosis (MESA) in 5,598 volunteer without baseline CHD, Mackey et al. showed that the association of HDL-C and carotid disease was considerably attenuated when taking into account atherogenic lipoproteins [18].”
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 1×
“The enthusiasm for EL inhibitors is somewhat tempered by Mendelian randomization data showing that variabilities at the EL and CETP genes that increase HDL-C are not associated with protection against CVD [143].”
BackgroundEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“Indeed in the Multi-Ethnic Study of Atherosclerosis (MESA) in 5,598 volunteer without baseline CHD, Mackey et al. showed that the association of HDL-C and carotid disease was considerably attenuated when taking into account atherogenic lipoproteins [18].”
MethodNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“Recent studies using fenofibrate in diabetic patients failed to show an effect on cardiovascular outcomes when LDL-Cwas controlled with statin therapy [19].”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · cited 3×
“HDL promotes vascular cell migration, proliferation, survival (antiapoptotic), and recruitment of endothelial progenitor cells (EPCs) to sites of vascular injury [17, 82].”
BackgroundMethodEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 1×
“It has been shown that cholesterol efflux from macrophages is strongly associated with atherosclerosis and provides better CVD prediction than plasma HDL-C levels [34].”
BackgroundNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“Early studies indicated that recombinant apoA-IMilano, when delivered by intravenous infusion, promotes regression of atherosclerosis lesion to a greater extent than wild type apoA-I as measured by intravascular ultrasound within 5 weeks of treatment [105].”
BackgroundMiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953 · cited 5×
“HDL phospholipids absorb cholesterol that diffuses from the plasma membrane by the interaction between HDL and SRBI [36, 37].”
BackgroundInfluentialEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 2×
“Anacetrapib therapy resulted in 138% increase inHDL-C, a 40% reduction in LDL-C, and a 36% decrease in Lp[a] [90].”
BackgroundInhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 1×
“Several biomarkers of oxidation potential have been put forth, by measuring the formation of biologically active oxidized phospholipids, by the determination of endothelial superoxide production and NADPH oxidase, or by the measurement of paraoxonase activity [73].”
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
miR-33 links SREBP-2 induction to repression of sterol transporters
Marquart, T. J., Allen, R. M., Ory, D. S., & Baldán, Á. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005191107 · Cited by 562 · cited 1×
“showed that injection of an anti-miR-33 oligonucleotide in mice resulted in a substantial increase in ABCA1 expression and HDL levels [172].”
BackgroundBesler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535 · cited 6×
“Activation of NO production involves HDL binding to SR-BI, which activates the phosphatidylinositol-3-kinase (PI3 K)/Akt signalling pathway and the phosphorylation of endothelial nitric oxide synthase (eNOS) [6].”
BackgroundResultInfluentialIntestinal ABCA1 directly contributes to HDL biogenesis in vivo
Brunham, L. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27352 · Cited by 519 · cited 1×
“Many tissues express ABCA1; the liver and intestine are the major organs contributing to plasma HDL-C levels [47, 48].”
BackgroundTimmins, J. M., Lee, J.-Y., Boudyguina, E., Kluckman, K. D., Brunham, L. R., Mulya, A., Gebre, A. K., Coutinho, J. M., Colvin, P. L., Smith, T. L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23915 · Cited by 447 · cited 1×
“Many tissues express ABCA1; the liver and intestine are the major organs contributing to plasma HDL-C levels [47, 48].”
BackgroundDavidson, W. S., Silva, R. A. G. D., Chantepie, S., Lagor, W. R., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.186031 · Cited by 415
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · cited 1×
“Clinical trials with evacetrapib showed substantially increased HDL-C (54–129%) and decreased LDL-C (14–36%) across a dose range of evacetrapib in 398 dyslipidemic patients [93].”
BackgroundGaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402 · cited 5×
“HDL from these patients reflects a shift to an inflammatory profile which, in turn, might alter the protective effects of HDL on the atherosclerotic plaque [73, 79].”
BackgroundInfluentialHorie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384
van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S. G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.060 · Cited by 374
Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337
Genetic Variant of the Scavenger Receptor BI in Humans
Vergeer, M., Korporaal, S. J. A., Franssen, R., Meurs, I., Out, R., Hovingh, G. K., Hoekstra, M., Sierts, J. A., Dallinga-Thie, G. M., Motazacker, M. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0907687 · Cited by 317 · cited 2×
“to have decreased risk of coronary artery disease [137], but this association has not been observed in other studies [64].”
BackgroundResultChapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298 · cited 1×
“The Determining Efficacy and Tolerability (DEFINE) trial randomized 1623 patients with CAD whose statin treatment has achieved LDL < 100mg/dL to 100mg of anacetrapib or placebo [89, 90].”
BackgroundBruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273 · cited 1×
“Later, a meta-analysis study of 11 randomized controlled trials, using niacin (none in monotherapy), was shown to significantly reduce major coronary events by 25%, stroke by 26%, and all cardiovascular events by 27% [98].”
BackgroundNovel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
Cited by
Ouimet, M., Barrett, T. J., & Fisher, E. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 761
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
Castella, B., Kopecka, J., Sciancalepore, P., Mandili, G., Foglietta, M., Mitro, N., Caruso, D., Novelli, F., Riganti, C., & Massaia, M. (2017) · Nature Communications · doi:10.1038/ncomms15663 · Cited by 82
Hafiane, A., Bielicki, J. K., Johansson, J. O., & Genest, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131997 · Cited by 57
Self-citation
Metadata
- Authors
- Hafiane, A., & Genest, J.
- Venue
- Cholesterol
- Publisher
- Wiley
- Published
- 2013-05-28
- Volume
- 2013
- Pages
- 1-18
- ISSN
- 2090-1283 (ISSN-L)
- 2090-1291
- OpenAlex
- W2047908649
- Cited by
- 80
- References
- 31
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.